MASP1

Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit

Retrieved on: 
Vendredi, octobre 16, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Immune system, Branches of biology, Proteins, Lectins, Mannan-binding lectin, Complement system, Alternative complement pathway, Biology, MASP1, MASP2, OMS906, Omeros Corporation

Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit.
  • OMS906 is the companys lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement systems alternative pathway.
  • Data also showed that lowest levels of detectable mature CFD correlated with complete inactivation of the alternative pathway.
  • Omeros expects OMS906 to have broad application in conditions involving inflammation and tissue damage as well as disorders associated with dysregulation of the alternative pathway.